ATOS Stock Chart & Stats
$44.70
$0.81(1.93%)
At close: 4:00 PM EDT
$44.70
$0.81(1.93%)
Day’s Range― - ―
52-Week Range$31.00 - $255.00
Previous CloseN/A
Volume25.00
Average Volume (3M)65.00
Market Cap
$406.83M
Enterprise Value-$9.01M
Total Cash (Recent Filing)$26.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Nov 16, 2026EPS Estimate
-16.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.34
Shares Outstanding9,979,298
10 Day Avg. Volume174
30 Day Avg. Volume65
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.94
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$328.77Price Target Upside635.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-69.94
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure removes refinancing obligations and interest-rate exposure, giving Atossa greater flexibility while it funds clinical development. This is particularly valuable for a clinical-stage company because capital can remain focused on research rather than debt servicing, although it does not eliminate funding needs.
Clinical Pipeline ProgressCompletion of Phase 2 enrollment in EVANGELINE and progress in I-SPY2 demonstrate that Atossa is advancing its lead oncology program through meaningful development milestones. Continued execution can improve the pipeline’s strategic value and create future regulatory or partnership opportunities.
Rare-disease OptionalityThe two FDA rare pediatric disease designations create a potential pathway to priority review voucher value alongside the core oncology pipeline. The CVR structure also aligns shareholders with that potential, though any proceeds depend on approval, voucher award, monetization, and distributable cash.
Bears Say
No Commercial RevenueAtossa has no commercial product revenue, so its operations and development programs are not yet supported by recurring sales. This leaves the company dependent on external financing or future clinical and regulatory success, making the business model less resilient than a revenue-generating biotechnology company.
Worsening Losses And Cash BurnThe company remains substantially unprofitable while operating cash outflows have increased from about $21.0 million in 2024 to $35.8 million on a TTM basis. Persistent and rising burn reduces financial flexibility and increases the importance of securing capital before later-stage programs mature.
Shrinking Equity BaseThe steep decline in stockholders’ equity reflects cumulative losses and ongoing cash usage, indicating that the company has consumed a substantial portion of its capital base. If this trend continues, Atossa may need additional financing, creating continued dilution and funding pressure for shareholders.
Atossa Therapeutics News
ATOS FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was $31.00 and its highest was $255.00 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is $406.83M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 15 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Aug 07, 2026. The company reported -$17.847 earnings per share for the quarter, beating the consensus estimate of -$19.256 by $1.409.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -16.1.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 9,979,298 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$17.847 in its last earnings report, beating expectations of -$19.256. Following the earnings report the stock price went up 4.534%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in MX:ATOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
ATOS Stock 12 Month Forecast
Average Price Target
$328.77
▲(635.50% Upside)